patients require a second emergency surgery/urgent procedure and have prolonged clotting times.if potential re-bleeding would be life-threatening and prolonged clotting times are observed, or.recurrence of clinically relevant bleeding together with prolonged clotting times, or.In a subset of patients, recurrence of plasma concentrations of unbound dabigatran and concomitant prolongation of clotting tests have occurred up to 24 hours after administration of idarucizumab (see section 5.1).Īdministration of a second 5 g dose of idarucizumab may be considered in the following situations:
The recommended dose is 5 g idarucizumab (2 vials of 2.5 g/50 mL).
0 kommentar(er)
